Company intelligence / Profile preview

Biote

Ownership: Public · BTMD
Development stage: Commercial

Overview

Biote has performed over four million pellet insertions since its founding. Its method for bioidentical hormone replacement therapy has been adopted by thousands of certified providers across the US. Clinical outcomes focus on symptom relief from hormonal imbalance with an emphasis on individualized care based on lab results and patient goals. The company also offers a line of nutraceuticals to complement its core BHRT offering.

Therapeutic areas: CardiovascularMen's HealthEndocrinologyImmunologyOtherWomen's Health
Modalities: Bioidentical hormone replacement therapy (BHRT) using subcutaneous pelletsnutraceuticals and cosmeceuticals
Industry: Biotech

Drug pipeline

1 asset

bioidentical hormone pellet implants

Unknown

Financials

Market cap: $57.8M
Total revenue: $44.2M
Enterprise value: $175.3M

Beyond the preview

Go deeper on Biote.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biote.

Explore the full profile